RESUMO
BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease depicted by synovial inflammation leading to local and systemic bone loss. The aim of this study was to evaluate by a HR-pQCT (High Resolution Peripheral Quantitative Computed Tomography) study which parameters are associated with volume of bone erosions including bone mineral density (BMD) around erosions (VOI 1 to 4 = volume of interest), BMD of metacarpophalangeal (MCP) head, BMD of radius, presence of osteophytes and joint space width (JSW). METHODS: Fifty female RA patients (18-50 years) were enrolled in this study. Demographic and disease-specific data, laboratory inflammatory parameters and handgrip test were performed. All patients underwent HR-pQCT of 2nd and 3rd MCP joints and distal radius, according to established protocols. The volume of bone erosions was evaluated by MIAF (Medical Image Analysis Framework) software. Osteophytes were analyzed by manual method. RESULTS: The mean of age and disease duration were 40.0 ± 6.0 yrs. and 10.8 ± 4.8 yrs., respectively. According to DAS-28 (Disease Activity Score), 54% (27) of the sample were in remission. However, when SDAI (Simplified Disease Activity Index) was used, only 18% (9) were under remission. The mean of HAQ (Health Assessment Questionnaire), ESR (Erythrocyte sedimentation rate) and CRP (C reactive protein) were 0.9 ± 0.7, 13.9 ± 12.2 mm and 5.6 ± 7.5 mg/mL, respectively. Forty-six bone erosions (0.9 ± 1.2 erosion/patient) and 14 osteophytes (0.3 ± 0.7 osteophyte/patient) were found in 2nd MCP head. The median (IQR-Interquartile range) of volume of erosion and volume of osteophytes were 14.9 (5.7;35.9)mm3 and 3.1 (2.1, 4.3)mm3, respectively. The mean of JSW was 80.5 ± 34.2 mm3. The volume of bone erosions was negatively correlated with BMD of 2nd MCP head, VOI-4 and JSW; and it was positively correlated with osteophytes number. Regarding absence or presence of erosion in 2nd MCP head, a significant difference was found between BMD of MCP head, osteophyte number and JSW. Multiple linear regression analysis showed that only BMD of 2nd MCP head was independently associated with volume of bone erosions. CONCLUSION: BMD of MCP head was independently associated with volume of bone erosion, suggesting that this parameter should be used to analyze and monitoring bone destruction, as well as to evaluate treatment response in RA patients.
Assuntos
Artrite Reumatoide , Densidade Óssea , Artrite Reumatoide/diagnóstico por imagem , Feminino , Força da Mão , Humanos , Articulação Metacarpofalângica/diagnóstico por imagem , Articulação do PunhoRESUMO
The Brazilian Societies of Rheumatology (SBR) and Dermatology (SBD), the Brazilian Federation of Gastroenterology (FBG) and the Brazilian Study Group on Inflammatory Bowel Disease (GEDIIB) gathered a group of their respective specialists on the topic of interest to discuss the most relevant issues regarding the clinical use of biosimilar medicines in Brazil. The main aim of that meeting was to prepare a document with recommendations to guide medical specialists and to help the national regulatory and policy-making agencies as concerns the authorization for marketing biosimilars used in autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, juvenile idiopathic arthritis and ulcerative colitis. In addition to considerations on the typical differences between innovator medicines and biosimilars, the specialists established a set of seven recommendations on regulatory advances related to clinical studies, indication extrapolation, nomenclature, interchangeability, automatic substitution and pharmacovigilance.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Medicamentos Biossimilares/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Animais , Brasil , Gastroenteropatias/tratamento farmacológico , Humanos , Sociedades MédicasRESUMO
INTRODUÇÃO: Os pacientes reumatológicos em terapia com antifator de necrose tumoral (anti-TNF, Tumor Necrosis Factor) são considerados imunodeprimidos. Neste sentido, a pesquisa de doenças infecciosas nesta população é imperiosa devido à alta morbidade e, por vezes, mortalidade associada a este quadro. OBJETIVOS: O presente trabalho teve por objetivo avaliar a frequência de soropositividade para os seguintes agentes infecciosos: Treponema pallidum (sífilis), Trypanosoma cruzii (doença de Chagas), vírus da imunodeficiência humana adquirida (Human imunnodeficiency Virus - HIV) e hepatites B e C (HBV e HCV, respectivamente) em pacientes recebendo terapia anti-TNF. PACIENTES E MÉTODOS: Foram avaliados 143 pacientes reumatológicos em um estudo observacional, com artrite reumatoide, espondilite anquilosante, artrite psoriásica e outras doenças, em uso de terapia anti-TNF (adalimumabe, etanercepte e infliximabe) no período de setembro de 2007 a novembro de 2008. Foram coletados dados clínicos e demográficos, bem como uma amostra de sangue para a análise da presença de anticorpos contra os agentes infecciosos HIV (Aids), HBV e HCV (hepatites B e C, respectivamente), Treponema pallidum (sífilis) e Trypanosoma cruzii (doença de Chagas). RESULTADOS: A média de idade da população estudada foi de 45,78 ± 12,7 anos, sendo 60,1 por cento do sexo feminino e 76,9 por cento de cor branca. Treze (9 por cento) dos pacientes apresentaram pelo menos uma sorologia positiva. Nenhum dos pacientes apresentou sorologia positiva para o Trypanosoma cruzii (doença de Chagas), bem como para HIV. Somente dois (1,4 por cento) indivíduos apresentaram positividade para o Treponema pallidum (sífilis) (ELISA positivo e VDRL negativo). A frequência de anti-HBc total foi de 5 por cento (7/140), sendo que todos estes foram positivos também para anti-HBs. O HBsAg foi negativo em todos os pacientes. Quatro pacientes tiveram HCV positivo, sendo que dois deles tinham PCR negativo para o vírus e outros...
INTRODUCTION: Patients with rheumatic diseases treated with anti-tumor necrosis factor (anti-TNF) are considered to be immunosuppressed. Therefore, investigation for infectious diseases is mandatory in this population due to the high morbidity and, occasionally, mortality associated with this condition. OBJECTIVES: The objective of the present study was to evaluate the frequency of seropositivity for the following infectious agents: syphilis, Chagas' disease, acquired human immunodeficiency virus (HIV), and hepatitis B and C in patients under anti-TNF therapy. PATIENTS AND METHODS: This observational study evaluated 143 rheumatology patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and others, under anti-TNF therapy (adalimumab, etanercept, and infliximab) from September 2007 to November 2008. Clinical and demographic data, as well as presence of antibodies against HIV, hepatitis B and C, syphilis, and Chagas' disease, were evaluated. RESULTS: The study population had a mean age of 45.78 ± 12.7 years; 60.1 percent were females and 76.9 percent Caucasian. Thirteen (9 percent) patients had at least one positive serology. None of the patients had antibodies to Chagas' disease and HIV. Only two (1.4 percent) individuals were positive for syphilis (positive ELISA and negative VDRL). The frequency of total anti-HBc was 5 percent (7/140), and those patients were also positive for anti-HBs. All patients were negative for AgHBs. Four patients were HCV positive: and two of them had negative virus PCR and the other two were positive, but they were stable. CONCLUSION: The frequency of seropositivity for different infectious diseases in patients under anti-TNF therapy is low. Individuals with positive serology for hepatitis C deserve close attention.
Assuntos
Humanos , Masculino , Feminino , Artrite Psoriásica , Artrite Reumatoide , Doença de Chagas , Hepatite A , Hepatite B , HIV , Doenças Reumáticas , Espondilite Anquilosante , Sífilis , Fatores de Necrose TumoralRESUMO
A artrite idiopática juvenil (AIJ) é uma doença crônica que pode evoluir para uma incapacidade permanente, necessitando muitas vezes de tratamento agressivo. Enquanto alguns pacientes não respondem ao metotrexato ou imunossupressores, outros não os toleram. Nestes casos, o uso dos inibidores de fator de necrose tumoral (TNF) ou anti-TNF é indicado. Conforme demonstrado por estudos multicêntricos e randomizados, o etanercepte apresenta eficácia no controle da doença, com efeito máximo nos primeiros três meses e até dois anos de tratamento contínuo. Não há publicação de estudos controlados com o infliximabe nem com o adalimumabe, mas seus efeitos parecem ser semelhantes aos do etanercepte. Estes agentes são relativamente seguros, podendo ser observadas complicações infecciosas, como a tuberculose e o herpes zoster. Raramente, podem ocorrer eventos auto-imunes, linfoproliferativos e sintomas gerais, como febre e cefaléia. No entanto, é importante salientar que apesar dos inibidores do TNF serem benéficos para muitas crianças com AIJ refratária, seus efeitos colaterais a longo prazo permanecem indefinidos, de forma que sua indicação deve ser criteriosa. Ademais, o alto custo destas drogas limita seu uso, especialmente em nosso país.